about
The Role of Cell-Penetrating Peptide and Transferrin on Enhanced Delivery of Drug to BrainNanotechnology-based drug delivery systems for the treatment of Alzheimer's diseaseLipid Nanoparticles for Ocular Gene DeliveryGetting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrierEvolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.Liposomes as nanomedical devicesUltrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.Immunoliposomal systems targeting primary effusion lymphoma: in vitro study.Tat-haFGF14-154 Upregulates ADAM10 to Attenuate the Alzheimer Phenotype of APP/PS1 Mice through the PI3K-CREB-IRE1α/XBP1 Pathway.Advances in strategies to improve drug delivery to brain tumors.Viral and nonviral delivery systems for gene deliveryIntravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains.A review on composite liposomal technologies for specialized drug delivery.Optimization on Preparation Conditions of Salidroside Liposome and Its Immunological Activity on PCV-2 in Mice.Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging.Refractory epilepsy: mechanisms and solutions.Biomaterials for the central nervous systemAntitumor efficacy and intratumoral distribution of SN-38 from polymeric depots in brain tumor modelGlutathione metabolism and Parkinson's disease.Imaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots.Targeting anti-HIV drugs to the CNS.Nanotechnology for delivery of drugs to the brain for epilepsy.Astrocyte-derived endothelin-1 inhibits remyelination through notch activation.Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer's disease treatment.Targeting liposomes toward novel pediatric anticancer therapeutics.Nanoparticulate systems for drug delivery and targeting to the central nervous system.Shuttle-mediated drug delivery to the brain.Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept.Liposomes and their applications in molecular imaging.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine.From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF)Strategies for drug delivery to the central nervous system by systemic route.Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.Drug delivery from gelatin-based systems.Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.Transferrin liposomes of docetaxel for brain-targeted cancer applications: formulation and brain theranostics.The impact of formulation attributes and process parameters on black seed oil loaded liposomes and their performance in animal models of analgesia.Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies.Rafts, Nanoparticles and Neural Disease
P2860
Q26745586-69EB1DC0-9EBF-47D5-A457-472BAD1FECC9Q26783306-D851AC52-A1CB-4F37-81C5-3AC26854273EQ26823895-B68B06F8-14B9-4B84-BC1F-F86F3D226A03Q28071873-9D3FA492-7103-4B36-B6A0-F9EC2CFEC4B2Q28082016-415819E4-8C2D-437D-B91B-A7410BAE4D20Q28088315-C907B459-2B70-4077-9493-3569BEAE00BEQ28539271-62748B3F-0A09-4E80-B403-D68677988A5DQ33704280-34A4DF67-D873-4798-9044-03D72E7DD7FEQ33726281-B9098714-07AF-42A3-A3F1-A9D6E5D43B55Q34000631-8107C42A-FB0F-4B5E-B2FE-C2C9AE74CB90Q34315475-AA5CC2C3-0D64-4863-865D-442AF08A437DQ34591697-CE2BEBC4-6B12-4C69-AF8D-63B6222FCBCAQ34730109-47A2AB51-20F5-40B1-BEC8-99AC752143ADQ35283522-31D1DCDF-7014-4FFF-929E-F0956D77DC6CQ35972521-A42C6ED6-827D-4757-90FC-6404814CCCA4Q36419584-1D5290D7-6039-43F8-8162-7284284D20F2Q36777653-AE8F480B-1512-4A45-BFC7-72A3C865AF44Q37071367-438F572F-E216-4907-9830-3089D4EA5F67Q37078480-A83F4678-39CB-433F-98AF-F8AEE763B431Q37167336-297D7E25-AC6C-49A6-AA4A-B8F8ED0C3623Q37368323-142F096C-FFAE-4AFA-A5B4-62803BC6BBD1Q37426991-8F814148-CB66-4A23-8C54-07CD9F0781F3Q37604029-68AAAFDC-FE3C-488E-99C3-019C1EBC749EQ37684641-AE354DB2-60F2-4686-9E87-D4A3F4522100Q37684734-2F164AC4-30E3-4EE2-884E-FF881EADE16AQ37800505-D9CC0A70-4129-4D76-B3BF-319178463C91Q37896550-D48C7BC8-D054-4995-AE42-1438AAF86333Q37999793-9995A622-3DEE-4115-AF95-60610C481D42Q38007179-A058C53E-0F44-4486-8067-1CE4EBDC217BQ38072598-1DBEFB0C-49F3-483B-8CBA-1187E7B6B884Q38163664-02DDB590-2184-4438-8401-DB20ED11EA17Q38168376-137A983F-1F8B-42A7-96F9-CC30AD2CD289Q38182668-C176DA6E-A225-494D-9BAB-A8D6AE312185Q38211727-77181270-3BA4-4472-8C31-147D96C9709DQ38460704-86CAAE82-850B-4CA7-BA1D-182B40F7D782Q38682342-0659BBFA-2D06-4590-A257-9D20E30C8703Q38787524-239D4662-5A97-49ED-B1E8-8F14819A6112Q38875216-BB5AFFE0-15B7-4A93-B158-8A0E7A53A57DQ39043216-C7B7BF54-7EBF-4BD7-84D8-654790C6D1D1Q39203564-4B31CC40-1E64-4E69-8B29-B1D136B21BB2
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Drug transport to brain with targeted liposomes
@ast
Drug transport to brain with targeted liposomes
@en
Drug transport to brain with targeted liposomes.
@nl
type
label
Drug transport to brain with targeted liposomes
@ast
Drug transport to brain with targeted liposomes
@en
Drug transport to brain with targeted liposomes.
@nl
prefLabel
Drug transport to brain with targeted liposomes
@ast
Drug transport to brain with targeted liposomes
@en
Drug transport to brain with targeted liposomes.
@nl
P2860
P356
P1433
P1476
Drug transport to brain with targeted liposomes
@en
P2093
Anita Schnyder
P2860
P304
P356
10.1602/NEURORX.2.1.99
P50
P577
2005-01-01T00:00:00Z